SCHEMBL144896

SCHEMBL144896

O=C(O)c1cccc(SSc2cccc(C(=O)O)c2O)c1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.65
ALDH1A1 P00352 5/20 0.55
KDM4E B2RXH2 4/20 0.55
HPGD P15428 2/20 0.55
HSD17B10 Q99714 2/20 0.55
ALB P02768 1/20 0.55
MMP2 P08253 1/20 0.55
HNF4A P41235 1/20 0.52
ALOX15 P16050 1/20 0.48
PSMD14 O00487 1/20 0.47
HMGB1 P09429 2/20 0.47
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA4 P22748 2/20 0.47
CA7 P43166 2/20 0.47
CA9 Q16790 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
CA6 P23280 1/20 0.46
NAPRT Q6XQN6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2960122 0.83 ALDH1A1 (0.57) POLBALDH1A1KDM4EHPGDHSD17B10
SCHEMBL110532 0.81 ALDH1A1 (0.70) POLBALDH1A1KDM4EHPGDHSD17B10
SCHEMBL144989 0.79 POLB (1.00) POLBALDH1A1KDM4EHPGDALOX15
SCHEMBL29380162 0.79 POLB (1.00) POLBALDH1A1KDM4EHPGDALOX15
SCHEMBL9755026 0.79 HPGD (0.52) POLBALDH1A1KDM4EHPGDHSD17B10
SCHEMBL27051667 0.79 ALB (0.52) POLBALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5832438 0.79 POLB (0.46) POLBALDH1A1KDM4EHPGDHSD17B10
Hydrochloric Acid SCHEMBL28210457 0.79 ALDH1A1 (0.67) POLBALDH1A1KDM4EHPGDHSD17B10
Methane SCHEMBL28154128 0.79 ALDH1A1 (0.67) POLBALDH1A1KDM4EHPGDHSD17B10
SCHEMBL28094410 0.79 ALDH1A1 (0.67) POLBALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012169077-A1 PROCESS FOR TREATING KERATIN FIBERS L'OREAL (FR) 2012-12-13 WO claimed
JP-9228081-A None JP disclosed
US-20140366905-A1 PROCESS FOR TREATING KERATIN FIBERS L'OREAL (FR) 2014-12-18 US disclosed
EP-2806850-A1 PROCESS FOR TREATING KERATIN FIBERS L'Oréal (FR) 2014-12-03 EP disclosed
WO-2013111346-A1 PROCESS FOR TREATING KERATIN FIBERS L'OREAL (FR) 2013-08-01 WO disclosed
WO-2012169077-A1 PROCESS FOR TREATING KERATIN FIBERS L'OREAL (FR) 2012-12-13 WO disclosed
US-20120058254-A1 ELECTROLESS PLATING SOLUTION, METHOD FOR ELECTROLESS PLATING USING THE SAME AND METHOD FOR MANUFACTURING CIRCUIT BOARD C. UYEMURA & CO., LTD. (JP) 2012-03-08 US disclosed
US-7569318-B2 double hydroxide salt contains monovalent and/or divalent, and also trivalent, metal cations (Mg, Ca, Zn, Co, Ni, Fe, Cu and Mn) and an aromatic acid (benzoic acid, naphthoic acid, 4-tert-butylbenzoic acid, benzenesulfonic acid, naphthalenesulfonic acid); influence electrostatic charging in a matrix CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) 2009-08-04 US disclosed
US-20060020069-A1 Use of salts of layered double hydoxides CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) 2006-01-26 US disclosed
JP-H09228081-A PICKLING SOLUTION FOR STAINLESS STEEL AND METHOD FOR PICKLING STAINLESS STEEL USING THE SOLUTION KAWASAKI STEEL CORP 1997-09-02 JP disclosed
US-4141734-A SUBSTITUTED ORGANIC DI- OR TRISULFIDE ANTIDEPOSIT AGENTS CIBA-GEIBY AG (CH) 1979-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140366905-A1 PROCESS FOR TREATING KERATIN FIBERS KRT18, CKAP4, HSPA4L POLB 966/4885ALDH1A1 791/4885KDM4E 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.